Could a tiny tablet under the tongue curb drinking and PTSD anxiety?
NCT ID NCT06335407
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 26 times
Summary
This early-phase study tests whether a sublingual form of dexmedetomidine (BXCL501) is safe and shows promise for reducing alcohol use and PTSD symptoms in heavy drinkers. Ten adults aged 21–65 with both alcohol use disorder and PTSD will take the drug daily for 28 days while researchers monitor side effects, blood pressure, anxiety, and PTSD symptoms. The goal is to gather enough safety and effectiveness data to plan larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER (AUD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
VA Connecticut Healthcare System
RECRUITINGWest Haven, Connecticut, 06516, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.